Boehringer Ingelheim International Gmbh

Zealand Pharma A/s

Boehringer Ingelheim (canada) Ltd.

Universitéde Montreal

Gilead Sciences, Inc.

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Marc-André Poupart

Jean Rancourt

Pierre Louis Beaulieu

Youla S Tsantrizos

Montse Llinas-Brunet

Murray D Bailey

Bruno Simoneau

James Gillard

Eric Jolicoeur

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

George Kukolj

Andrew Roughton

Jennifer L Hickey

Manuel Perez Vazquez

Gaoqiang Yang

Adam Paul Kafal

M Monzur Morshed

Martin Poirier

Sylvie Goulet

Punit R Bhardwaj

Dale R Cameron

Anne-Marie Faucher

Gulrez Fazal

Dominik M Wernic

Stephen Kawai

Christian Brochu

Serge R Landry

Rebekah J Carson

Pasquale Forgione

Mathieu Parisien

Catherine Chabot

Sai Kumar Chakka

Steven LaPlante

René Coulombe

Araz Jakalian

Narendra Patel

Punit K Bhardwaj

François Bilodeau

Lee Fader

Andrew L Roughton

Paul J Edwards

Sébastien Morin

Dale Cameron

There is described herein antagonists of &#x3b1;4&#x3b2;7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R, R, R, R, R, R, Rand Rare various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; &#x2014;C&#x2550;O&#x2014; adjacent L is the carboxy terminus of an amino acid; and L along with Z and &#x2014;C&#x2550;O&#x2014; is a peptide. 

Cyclic peptides targeting alpha-4-beta-7 integrin

There is described herein use of a compound of formula (I) below to make cyclic peptides. 

Fragment synthesis of substituted cyclic peptides

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: wherein Rand Rand Q are as defined herein;

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R, R, L, M, M, M, M, Y, Y, Z and Sp are as defined in claimor a salt thereof, as an inhibitor of HCV NS5B polymerase.

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R, R, M, M, M, M, Yand Z are as defined in claim, or a salt thereof, as an inhibitor of HCV NS5B polymerase.

Compounds of formula (I): wherein R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor peptide analogs

Compounds of formula (I): wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor dipeptide analogs

A racemate diastereoisomer and optical isomer of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

Hepatitis C inhibitor tri-peptides

The HCV NS5B polymerase, when complexed with certain inhibitors, adopts a conformation in which the finger loop region defined by amino acid residues 18 to 35 is displaced to expose a binding pocket defined generally by amino acid residues 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 and 503. This newly exposed binding pocket defines a novel target in the search of further chemical entities which are capable of binding to HCV NS5B and modulating, or preferably inhibiting, the polymerase activity of HCV NS5B.

Hepatitis C Virus NS5B polymerase inhibitor binding pocket

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein wherein A, B, R, R, M, M, M, M, Yand Z are as defined in claim, or a salt thereof, as an inhibitor of HCV NS5B polymerase.

Growing community of inventors

Laval, Canada

Marc-André Poupart